Nautilus Biotechnology reported a narrower-than-expected loss for the third quarter of 2026 and recognized its first material revenue from grants and early access services. While the company continues to operate in its pre-commercial phase, management reaffirmed a development roadmap that targets full instrument availability for its single-molecule proteomics platform by mid-2027.
Key Highlights
- Net loss of $0.12 per share outperformed analyst estimates of a $0.14 loss, driven by disciplined spending and unexpected grant revenue.
- Total revenue reached $0.23 million, primarily sourced from a Michael J. Fox Foundation grant and the Iterative Mapping Early Access Program.
- Operating expenses rose 10% year-over-year to $16.9 million as the company increased investments in laboratory services and personnel to scale its proteoform pipeline.
- Total liquidity, including cash and investments, stood at $114.3 million as of September 30, 2026, compared to $156.1 million at the end of fiscal 2025.